Vermillion's Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Sta... (hey can be referred to a gynecologic onc...)

Vermillion's Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease

Date:3/10/2008

hey can be referred to a gynecologic oncologist for their initial surgery. Vermilion intends to submit clinical trial data on the Ovarian Tumor Triage

Test to the U.S. Food and Drug Administration for clearance as an in vitro diagnostic test in the first half of 2008.

Additionally, studies are underway to detect early-stage ovarian cancer, predict prognosis and recurrence, and identify women considered at high-risk for the disease.

Vermillion's comprehensive diagnostic development program is being conducted with several leading collaborators at The Johns Hopkins School of Medicine, The University of Texas M.D. Anderson Cancer Center, Rigshospitalet (Copenhagen), and the University of Kentucky.

About Ovarian Cancer

According to the American Cancer Society (ACS), approximately 22,430 new cases of ovarian cancer will be diagnosed this year, and 15,280 deaths will be reported as a result of the disease. When diagnosed at its earliest stages, ovarian cancer has a 5-year survival rate of 93 percent. However, only 19 percent of ovarian cancers are diagnosed before the tumor has spread outside the ovary. For late-stage disease, the 5-year survival rate falls to 18 percent.

New diagnostic tests are needed to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90 percent cure rate following surgery and/or chemotherapy if detected in stage 1.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is b
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
2. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
3. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
4. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
9. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
10. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
11. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function

Post Your Comments:

(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, Systemic Lupus ... Market Forecasts to 2015 ,, ... Lupus Erythematosus - Drug Pipeline Analysis ... Summary ,, GlobalData, the ...

(Date:12/15/2009)... December 15 EnzySurge Ltd.,(EnzySurge), a ... chronic,wound management market, announced today that it ... Drug Administration (FDA) to market its new,SilverStream(TM) ... cleared,DermaSept, an Over-the-Counter version of the SilverStream ... is the developer of the DermaStream(R) product ...

(Date:12/15/2009)... 15 NxStage Medical, Inc. (Nasdaq: ... products, today announced that a group of its ... embarking on a week-long, conventional (non-dialysis) Caribbean cruise ... cruise, dubbed the "2010 Freedom Cruise: We,re Taking ... on January 3, 2010 and returns on January ...

Breaking Medicine Technology:Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 2 Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 3 Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 4 Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 5 Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 6 Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 7 Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 8 EnzySurge Receives FDA Approval for SilverStream(TM) Innovative Wound Management Solution 2 Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 2 Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 3 Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 4 Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 1 Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 2 Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 3 Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 4 Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 5 Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 6 Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 7 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 1 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 2 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 3 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 4 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 5 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 6 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 7 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 8 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 9 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 10 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 11 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 12 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 13 PDI Reports 2009 Third Quarter Financial Results 6023 1 PDI Reports 2009 Third Quarter Financial Results 6023 2 PDI Reports 2009 Third Quarter Financial Results 6023 3 PDI Reports 2009 Third Quarter Financial Results 6023 4 PDI Reports 2009 Third Quarter Financial Results 6023 5 PDI Reports 2009 Third Quarter Financial Results 6023 6 PDI Reports 2009 Third Quarter Financial Results 6023 7 PDI Reports 2009 Third Quarter Financial Results 6023 8 PDI Reports 2009 Third Quarter Financial Results 6023 9 PDI Reports 2009 Third Quarter Financial Results 6023 10 PDI Reports 2009 Third Quarter Financial Results 6023 11

[0] Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 [0] EnzySurge Receives FDA Approval for SilverStream(TM) Innovative Wound Management Solution [0] Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM)

... BALTIMORE, Dec. 10 Data by Dr. J. Bart Classen ... Research & Reviews provides further evidence that epidemics of ... to immunization. Classen previously published proof vaccines are causing an ... , The new data as well ...

... results from a Phase 1/2 study of perifosine in ... relapsed from or refractory to bortezomib , ... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today ... in combination with bortezomib (+/- dexamethasone) in patients with ...

Other Medicine Technology:Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization 2 Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 7

Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

(Date:12/15/2009)... examines potential for injury when doctors decide benefits of ... News) -- MRI scans can pose a serious risk ... Food and Drug Administration researchers exposed pacemakers to a ... voltage produced at the tip of the pacemaker lead, ... heart. , The exposure to MRI magnetic pulses caused ...

(Date:12/15/2009)... as accurate a surgical method, with fewer complications, analysis ... it comes to diagnosing breast cancer, women and their ... the less invasive "core needle biopsy" procedure is nearly ... surgical procedure is, with fewer complications than the surgical ... the Jan. 5 issue of Annals of Internal ...

(Date:12/15/2009)... NEW YORK, Dec. 15 ... research report is available in its ... Manufacturing Industry in the U.S. and ... ,, http://www.reportlinker.com/p0167482/In-Vitro-Diagnostic-Substance-Manufacturing-Industry-in-the-US-and-its-International-Trade-[Q4-2009-Edition].html ,, ... Manufacturing Industry report provides the latest ...

(Date:12/15/2009)... Mergers and acquisitions are commonplace today. As competitors ... complete a product portfolio they also must face ... ,, A new free, white paper from Howard ... Conservation Program: US Airways ," details how the ... the newly formed company to enhance its occupational ...

(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... - Market Forecasts to 2015, Competitive ... ,, http://www.reportlinker.com/p0168098/The-Future-of-Cardiovascular-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, ... has released its latest research "The ...

[0] Patients With Pacemakers Should Avoid MRI Scans [0] Needle Biopsy Works Well in Diagnosing Breast Cancer [0] Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition][0] New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways [0] Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

... may improve sensors in stagnant,environments, COLLEGE PARK, ... in coal mines, buildings or underground public transit,areas ... may one day be improved by,research on young ... Clark,School of Engineering., Mechanical engineers Ken Kiger ...

... told that exposure to radiation is dangerous. In high doses ... the development of cancer. But, what if a short-term controlled ... our health. Writing in today,s issue of the Inderscience publication ... makes the startling claim that low dose radiation could be ...

... to be the first health plan to ... care platform to consumers., SAN FRANCISCO, June ... Institute 2008, American Well Inc. and,Microsoft Corp. announced ... introduce an integrated consumer health solution that,brings together ...

... focus on eCare, an initiative that employs information,and ... integrate,environments of care, WILLIAMSBURG, Va., June 18 ... of William and Mary proudly announces that,Professor Dorothea ... the highest,academic awards available to a faculty member ...

... nearly two years and 95 pounds,lighter, Lisa Ashmore is a ... who she is., "I have ,before, and ,after, pictures ... says Lisa. "And when they say ,No, I say,You,re lookin, ... going through the Kronos,Weight Management progam provided by her employer ...

... of a human patient,s cloned infection-fighting T cells as the ... remission. A team led by Cassian Yee, M.D., an associate ... Research Center, reports these findings in the June 19 issue ... Yee and colleagues removed CD4+ T cells, a type of ...

Other Medicine News:Health News:Mayfly-Mimicking Sensor to Replace Proverbial Canary in the Coal Mine 2 Health News:Mayfly-Mimicking Sensor to Replace Proverbial Canary in the Coal Mine 3 Health News:Radiation for health 2 Health News:Radiation for health 3 Health News:American Well and Microsoft Enter Into a Strategic Collaboration to Bring Healthcare to People's Homes 2 Health News:American Well and Microsoft Enter Into a Strategic Collaboration to Bring Healthcare to People's Homes 3 Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 2 Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 3 Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 4 Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 5 Health News:Survey Indicates Lifestyle Change Is More Important Than Diets 2 Health News:Survey Indicates Lifestyle Change Is More Important Than Diets 3 Health News:Patient's own infection-fighting T cells put late-stage melanoma into long-term remission 2

Mayfly-Mimicking Sensor to Replace Proverbial Canary in the Coal Mine Radiation for health American Well and Microsoft Enter Into a Strategic Collaboration to Bring Healthcare to People's Homes Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar Survey Indicates Lifestyle Change Is More Important Than Diets Patient's own infection-fighting T cells put late-stage melanoma into long-term remission

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Chlamydia psittaci Chlamydia pneumoniae Antibody, IgG by ELISA Chlamydia Antibody Panel, IgM by IFA Chimerism, Recipient Pre-Transplant

Vermillion's Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Sta...(hey can be referred to a gynecologic onc...),Health